Engineering Modular Viral Scaffolds for Targeted Bacterial Population Editing

Bacteria are central to human health and disease, but existing tools to edit microbial consortia are limited. For example, broad-spectrum antibiotics are unable to accurately manipulate bacterial communities. Bacteriophages can provide highly specific targeting of bacteria, but assembling well-defined phage cocktails solely with natural phages can be a time-, labor- and cost-intensive process. Here, we present a synthetic-biology strategy to modulate phage host ranges by engineering phage genomes in Saccharomyces cerevisiae. We used this technology to redirect Escherichia coli phage scaffolds to target pathogenic Yersinia and Klebsiella bacteria, and conversely, Klebsiella phage scaffolds to target E. coli by modular swapping of phage tail components. The synthetic phages achieved efficient killing of their new target bacteria and were used to selectively remove bacteria from multi-species bacterial communities with cocktails based on common viral scaffolds. We envision that this approach will accelerate phage-biology studies and enable new technologies for bacterial population editing.

[1]  T. Dean,et al.  A Yersinia pestis-specific, lytic phage preparation significantly reduces viable Y. pestis on various hard surfaces experimentally contaminated with the bacterium , 2012, Bacteriophage.

[2]  H. Krisch,et al.  Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: recombination between conserved motifs swaps adhesin specificity. , 1998, Journal of molecular biology.

[3]  James J. Collins,et al.  Dispersing biofilms with engineered enzymatic bacteriophage , 2007, Proceedings of the National Academy of Sciences.

[4]  H. Brüssow What is needed for phage therapy to become a reality in Western medicine? , 2012, Virology.

[5]  R. Hausmann,et al.  The gene for Klebsiella bacteriophage K11 RNA polymerase: Sequence and comparison with the homologous genes of phages T7, T3, and SP6 , 1990, Molecular and General Genetics MGG.

[6]  Timothy K Lu,et al.  The next generation of bacteriophage therapy. , 2011, Current opinion in microbiology.

[7]  G. Church,et al.  CRISPR/Cas9-Mediated Phage Resistance Is Not Impeded by the DNA Modifications of Phage T4 , 2014, PloS one.

[8]  U. Fano,et al.  Bacteriophage-Resistant Mutants in Escherichia Coli. , 1945, Genetics.

[9]  D. G. Gibson Oligonucleotide assembly in yeast to produce synthetic DNA fragments. , 2012, Methods in molecular biology.

[10]  I. Molineux,et al.  The Genome Sequence of Yersinia pestis Bacteriophage φA1122 Reveals an Intimate History with the Coliphage T3 and T7 Genomes , 2003, Journal of bacteriology.

[11]  C. Richardson,et al.  New Details about Bacteriophage T7-Host Interactions: Researchers are showing renewed interest in learning how phages interact with bacterial hosts, adapting to and overcoming their defenses , 2010 .

[12]  D. Endy,et al.  A fully decompressed synthetic bacteriophage øX174 genome assembled and archived in yeast. , 2012, Virology.

[13]  Timothy B. Stockwell,et al.  Complete Chemical Synthesis, Assembly, and Cloning of a Mycoplasma genitalium Genome , 2008, Science.

[14]  Chad W. Euler,et al.  Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials , 2014, Nature Biotechnology.

[15]  Mikael Skurnik,et al.  Complete nucleotide sequence and likely recombinatorial origin of bacteriophage T3. , 2002, Journal of molecular biology.

[16]  Irene A. Chen,et al.  Inhibition of Bacterial Conjugation by Phage M13 and Its Protein g3p: Quantitative Analysis and Model , 2011, PloS one.

[17]  R. Hausmann The T7 Group , 1988 .

[18]  Timothy K Lu,et al.  Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy , 2009, Proceedings of the National Academy of Sciences.

[19]  F. D'Herelle Bacteriophage as a Treatment in Acute Medical and Surgical Infections. , 1931, Bulletin of the New York Academy of Medicine.

[20]  J. Morris,et al.  MINIREVIEW Bacteriophage Therapy , 2001 .

[21]  Mark J van Raaij,et al.  Structural Characterization of the Bacteriophage T7 Tail Machinery*♦ , 2013, The Journal of Biological Chemistry.

[22]  Molly K. Gibson,et al.  The yin and yang of bacterial resilience in the human gut microbiota. , 2014, Journal of molecular biology.

[23]  S. Moineau,et al.  CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages , 2014, Nucleic acids research.

[24]  Vincent Noireaux,et al.  Genome replication, synthesis, and assembly of the bacteriophage T7 in a single cell-free reaction. , 2012, ACS synthetic biology.

[25]  K. Miyanaga,et al.  Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. , 2005, Journal of biotechnology.

[26]  C. Rm Phage therapy: past history and future prospects. , 1999 .

[27]  Bo Hu,et al.  The Bacteriophage T7 Virion Undergoes Extensive Structural Remodeling During Infection , 2013, Science.

[28]  Andrey P. Anisimov,et al.  Identification of the Lipopolysaccharide Core of Yersinia pestis and Yersinia pseudotuberculosis as the Receptor for Bacteriophage φA1122 , 2011, Journal of bacteriology.

[29]  H. Krisch,et al.  The gp38 Adhesins of the T4 Superfamily: A Complex Modular Determinant of the Phage’s Host Specificity , 2011, Genome biology and evolution.

[30]  M. Kleerebezem,et al.  Microbiome and skin diseases , 2013, Current opinion in allergy and clinical immunology.

[31]  T. Dinan,et al.  Mind-altering Microorganisms: the Impact of the Gut Microbiota on Brain and Behaviour , 2022 .

[32]  F. Studier,et al.  Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements. , 1983, Journal of molecular biology.

[33]  M Unser,et al.  Molecular substructure of a viral receptor-recognition protein. The gp17 tail-fiber of bacteriophage T7. , 1988, Journal of molecular biology.

[34]  Schuyler F. Baldwin,et al.  The Complete Genome Sequence of Escherichia coli DH10B: Insights into the Biology of a Laboratory Workhorse , 2008, Journal of bacteriology.

[35]  Shun-Fu Chang,et al.  A T3 and T7 Recombinant Phage Acquires Efficient Adsorption and a Broader Host Range , 2012, PloS one.

[36]  U. Qimron,et al.  Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system , 2014, RNA biology.

[37]  M. Chamberlin,et al.  Isolation of recombinants between T7 and T3 bacteriophages and their use in vitro transcriptional mapping , 1977, Journal of virology.

[38]  J. Segre,et al.  The human microbiome: our second genome. , 2012, Annual review of genomics and human genetics.

[39]  Flavie Pouillot,et al.  Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria. , 2010, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[40]  R. Hendrix Bacteriophage genomics. , 2003, Current opinion in microbiology.

[41]  W. Bessler,et al.  A bacteriophage-induced depolymerase active on Klebsiella K11 capsular polysaccharide. , 1973, Virology.

[42]  R. Carlton,et al.  Phage therapy: past history and future prospects. , 1999, Archivum immunologiae et therapiae experimentalis.

[43]  Timothy K Lu,et al.  Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases , 2014, Nature Biotechnology.

[44]  Christopher T. Walsh,et al.  Antibiotics for Emerging Pathogens , 2009, Science.